Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04129398
Other study ID # 8228-042
Secondary ID MK-8228-04219502
Status Completed
Phase Phase 3
First received
Last updated
Start date December 27, 2019
Est. completion date October 6, 2022

Study information

Verified date September 2023
Source Merck Sharp & Dohme LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to evaluate the safety, efficacy and pharmacokinetics (PK) of Letermovir (LET) administered as prevention of cytomegalovirus (CMV) infection and disease in adult Japanese kidney transplant recipients.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date October 6, 2022
Est. primary completion date October 6, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Meets recipient and/or donor CMV Immunoglobulin G (IgG) serostatus. - Anticipates receiving a primary or secondary allograft kidney at the time of screening and have received a primary or secondary allograft kidney at the time of allocation. - Is within 0 (i.e., day of transplantation) to 7 days (inclusive) post-kidney transplant at the time of allocation. - Is a Japanese male or female from 18 years to any years of age inclusive, at the time of signing the informed consent. - Female is not pregnant or breastfeeding, and is not a woman of childbearing potential (WOCBP); but if a WOCBP, she is using an acceptable contraceptive method, or is abstinent from heterosexual intercourse, and must have a negative highly sensitive pregnancy test within 72 hours before the first dose of study intervention. Exclusion Criteria: - Has received a previous solid organ transplant or hematopoietic stem cell transplant (HSCT). - Is a multi-organ transplant recipient (e.g., kidney-pancreas). - Has a history of CMV disease or suspected CMV disease within 6 months prior to allocation. - Has positive results on CMV assay and/or CMV antigen test at any time between the completion of the transplant surgery and time of allocation. - Has suspected or known hypersensitivity to active or inactive ingredients of LET formulations. - Is on dialysis (for the purposes of this protocol dialysis includes hemofiltration) or plasmapheresis at the time of allocation. - Has Child-Pugh Class C severe hepatic insufficiency at screening. - Has post-transplant renal function of creatinine clearance (CrCl) =10 mL/min at allocation (measured locally). - Has both moderate hepatic insufficiency AND moderate-to-severe renal insufficiency at screening. - Has any uncontrolled infection on the day of allocation. - Has documented positive results for human immunodeficiency virus antibody (HIV-Ab) test at any time prior to allocation, or for hepatitis C virus antibody (HCV-Ab) and with detectable HCV RNA within 90 days prior to allocation or hepatitis B surface antigen (HBsAg) within 90 days prior to allocation. - Requires mechanical ventilation, or is hemodynamically unstable, at the time of allocation. - Has a history of malignancy =5 years prior to signing informed consent. - Has received within 30 days prior to allocation or plans to receive during the study any of the following: CMV immune globulin; any investigational CMV antiviral agent/biologic therapy. - Has received any dose of LET prior to allocation. - Has received within 7 days prior to allocation or plans to receive during the study any anti-CMV drug therapy. - Is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence. - Is taking or plans to take any of the prohibited medications listed in the protocol. - Is currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5× half-life of the investigational compound. - Has previously participated in this study or any other study involving LET. - Has previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent, or is planning to participate in a study of a CMV vaccine or another CMV investigational agent during the course of this study. - Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through at least 28 days following cessation of study therapy. - Is expecting to donate eggs starting from the time of consent through at least 28 days following cessation of study therapy.

Study Design


Intervention

Drug:
Letermovir tablet
A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks
Letermovir IV
IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks

Locations

Country Name City State
Japan Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital ( Site 0002) Nagoya Aichi
Japan Sapporo City General Hospital ( Site 0004) Sapporo Hokkaido
Japan Osaka University Hospital ( Site 0003) Suita Osaka
Japan Tokyo Women's Medical University Hospital ( Site 0001) Tokyo

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Adverse Events (AEs) Percentage of participants with one or more adverse events (AEs) Up to week 52 post-transplant
Primary Percentage of Participants Who Discontinued From Study Drug Due to an AE Percentage of participants who discontinued from study drug due to an AE Up to week 28 post-transplant
Secondary Percentage of Participants With Adjudicated CMV Disease or Undergone Anti-CMV Treatment CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded Clinical Adjudication Committee (CAC). Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included. Participants who have undergone anti-CMV treatment was defined as initiation of approved anti-CMV agents based on at least one positive cell on CMV antigenemia and/or quantifiable CMV DNA PCR assay performed locally. Up to Week 52 post-transplant
Secondary Percentage of Participants With Adjudicated CMV Disease CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded Clinical Adjudication Committee (CAC). Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included. Up to Week 52 post-transplant
Secondary Percentage of Participants With Quantifiable CMV DNAemia Quantifiable CMV DNAemia (central) was defined as any case with a numeric value or >910,000,000 (not including reporting of PCR results as "detected, not quantifiable") using the Roche COBAS® AmpliPrep/COBAS TaqMan® (CAP/CTM) assay, which was performed by the central laboratory. Up to Week 52 post-transplant
Secondary Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Plasma Letermovir-oral Treatment AUCtau was defined as a measure of letermovir exposure that was calculated as the product of plasma drug concentration and time following an oral administration of letermovir. Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Secondary Trough Concentration (Ctrough) of Plasma Letermovir - Oral Treatment Ctrough was defined as the minimum concentration of letermovir that occurred immediately following an oral administration of letermovir. Any day between Days 6-10: 24hrs post-dose
Secondary Maximum Concentration (Cmax) of Plasma Letermovir - Oral Treatment Cmax was defined as the maximum concentration of letermovir observed in plasma following an oral administration of letermovir. Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Secondary Time to Reach Cmax (Tmax) of Plasma Letermovir - Oral Treatment Tmax was defined as the time required post dosing to reach a maximum plasma concentration of letermovir following an oral administration of letermovir. Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Secondary Apparent Clearance at Steady State (CLss/F) of Plasma Letermovir - Oral Treatment Apparent clearance at steady state (CLss/F) of plasma letermovir following an oral administration of letermovir. Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Secondary Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Plasma Letermovir - IV Treatment AUCtau was defined as a measure of letermovir exposure that was calculated as the product of plasma drug concentration and time following an IV administration of letermovir was intended to measure. Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Secondary Trough Concentration (Ctrough) of Plasma Letermovir - IV Treatment Ctrough was defined as the minimum concentration of letermovir that occurred immediately following an IV administration of letermovir was intended to measure. Pre-dose on Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 and 28
Secondary Concentration at the End of Infusion (Ceoi) of Plasma Letermovir - IV Treatment Ceoi is defined as the amount of letermovir in plasma following an IV administration of letermovir was intended to measure. Any day between Days 6-10: at end of infusion (1 hours post dose)
Secondary Clearance at Steady State (CLss) of Plasma Letermovir - IV Treatment Clearance at steady state (CLss) of plasma letermovir following an IV administration of letermovir was intended to measure. Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
See also
  Status Clinical Trial Phase
Completed NCT00023036 - Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Terminated NCT01037712 - In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Phase 4
Completed NCT00370006 - Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT01552369 - CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") Phase 4
Completed NCT00223925 - Maribavir for Prevention of CMV After Stem Cell Transplants Phase 2
Active, not recruiting NCT05085366 - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Phase 3
Completed NCT01220895 - Alternate Donor Study of Pre-Emptive Cellular Therapy Phase 2
Completed NCT00942305 - Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients Phase 2
Completed NCT00373412 - Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge Phase 1
Completed NCT05105048 - A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 Phase 1
Completed NCT00386412 - TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant Phase 2
Completed NCT03382405 - Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults Phase 1
Completed NCT02454699 - Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers Phase 1
Active, not recruiting NCT03910478 - Dried Blood Spot Testing of CMV Detection in HCT Recipients N/A
Completed NCT01354301 - Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Phase 4
Active, not recruiting NCT01473849 - Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients N/A
Completed NCT00880789 - Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus Phase 1
Completed NCT00817908 - Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients N/A
Completed NCT00273143 - A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients. Phase 1